Post-traumatic stress disorder (PTSD) has a profound impact not only on those with this diagnosis but on their friends and families as well.  PTSD affects five out of every 100 adults in the United States, amounting to approximately 13 million Americans regardless of gender. Despite the prevalence of this condition, treatment options remain limited, often offering only short-term relief rather than addressing the root cause of the disorder.

There is, however, a new and promising treatment on the horizon: Methylenedioxymethamphetamine-Assisted Therapy (MDMA-AT). This innovative therapy has shown remarkable effectiveness in clinical trials, providing hope to those who have struggled with PTSD for years. Unlike traditional treatments, MDMA-AT addresses the underlying causes of PTSD symptoms.

It is critical that the Federal Drug Administration approves MDMA-AT in August. This decision could change the lives of millions of Americans who suffer from PTSD by offering the potential for lasting relief and healing.  

As a retired U.S. Marine, I have seen the desperate need for more effective treatments for this disorder, and currently MDMA-AT represents a significant advancement in this field. While the FDA’s advisory committee has initially recommended against this approval, organizations directly serving and daily administering care to our Veterans have advocated for the approval of this assisted therapy drug.   

By advocating for this treatment, and urging the FDA’s approval of MDMA-AT, Sen. Bob Casey and Sen. John Fetterman can help ensure that those suffering from PTSD receive the comprehensive care they need and a path toward the restorative health they deserve.

Barb Cross
Lt. Col. USMC Reserve (Ret.)
Carlisle, PA